642 filings
8-K
ENTO
Entero Therapeutics, Inc.
11 Sep 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:10pm
8-K
ENTO
Entero Therapeutics, Inc.
10 Sep 24
Regulation FD Disclosure
7:00am
8-K
ENTO
Entero Therapeutics, Inc.
3 Sep 24
Other Events
4:05pm
8-K
ENTO
Entero Therapeutics, Inc.
29 Aug 24
Changes in Registrant's Certifying Accountant
4:05pm
8-K
ENTO
Entero Therapeutics, Inc.
23 Aug 24
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
5:00pm
8-K
khbju25
22 Aug 24
Departure of Directors or Certain Officers
5:28pm
NT 10-Q
w9imtms
15 Aug 24
Notice of late quarterly filing
8:05am
8-K
37743bx
15 Aug 24
Changes in Registrant's Certifying Accountant
8:00am
3
5oa1ly
14 Aug 24
Entero Therapeutics / Timothy R. Ramdeen ownership change
9:46pm
8-K
s4todafy
7 Aug 24
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
5:20pm
8-K
2pkmhup4t6
31 Jul 24
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
10:54am
8-K
p0diejua41nlpqox
23 Jul 24
Departure of Directors or Certain Officers
4:05pm
8-K
c1ugn6ekk
11 Jul 24
Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds
8:00am
4
7nipwc h536
3 Jul 24
Entero Therapeutics / Sarah Romano ownership change
2:34pm
4
ya5kef2my qie
3 Jul 24
Entero Therapeutics / JAMES SAPIRSTEIN ownership change
2:33pm
S-8
ul0yyzq9s tnhmd
24 Jun 24
Registration of securities for employees
8:03am
8-K
z50a3m48tg rc
20 Jun 24
Departure of Directors or Certain Officers
4:30pm
424B3
7ngat7v
14 Jun 24
Prospectus supplement
5:15pm